AAVantgarde Bio

Next-generation therapies in IRDs

Milan, Italy · Founded 2021 · $207.0M raised

Headquarters
Milan
Employees
51–200
Founded
2021
Business Model
B2B
Total Funding
$207.0M
Last Round
$141.0M Series BNov 2025
Rounds
2

Totals include recorded grants and other qualifying funding, not just equity. What counts toward funding.

About

AAVantgarde Bio is a clinical-stage biotechnology company developing next-generation gene therapies for inherited retinal diseases with high unmet need, focused on Stargardt disease and Usher Syndrome Type 1B. Founded as a spin-off from the Telethon Institute of Genetics and Medicine (TIGEM) in Naples, Italy, and co-founded by Professor Alberto Auricchio, the company is headquartered in Milan, Italy. AAVantgarde has developed a proprietary dual AAV-intein platform capable of delivering large genes that exceed single AAV capsid capacity.

Summary

AAVantgarde Bio is a Biotech company based in Milan, Italy, founded in 2021. It has raised $207.0M in total across 2 rounds, most recently a $141.0M Series B round in Nov 2025. Investors include Atlas Venture, Forbion Capital Partners and Schroders.

Tech & App Stack

3 technologies & apps tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding History

Series BSeries BNov 2025
$141.0M

Sign up to see all 2 events

Funding: Series A through Series B. Amounts, valuations, and investors where available.

Investors

Similar Companies

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

AAVantgarde Bio on Indexed.vc
<a href="https://indexed.vc/companies/aavantgarde-bio"><img src="https://indexed.vc/api/badge/company/aavantgarde-bio" alt="AAVantgarde Bio on Indexed.vc" width="260" height="76" /></a>